Press Releases

07 April 2020

Alessandro Della Chà Appointed as Director of Acacia Pharma Group plc

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge, UK and Indianapolis, US – 7 April 2020: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that Alessandro Della Chà has been appointed to the Board as a non-executive Director.

This appointment is in accordance with the right of Cosmo Technologies Limited, a wholly owned subsidiary of Cosmo Pharmaceuticals N.V., to appoint a director to the Board under the terms of the strategic in-licensing, investment and loan transaction entered into in January 2020.

Alessandro Della Chà has been a board member of Cosmo Pharmaceuticals N.V. since 2006 and has been the Chief Executive Officer since 27 March 2014.

Until 27 March 2014, he was senior partner at Studio Legale Edoardo Ricci e Associati, Milan, where he specialized in company law, mergers and acquisitions. He joined the firm in 1988. From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest Group. From 1994 to 1998 he was director of II.PP.A.B. Milan (formerly ECA), a charitable institution owning hospitals and specialized in elderly care.

Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. in European Union commercial law from the University of Leicester, United Kingdom. He is a lecturer in conferences and seminars held by universities and institutions on commercial and company law issues.

Commenting, Scott Byrd, Chairman, said: “I am delighted to welcome Alex as a company director. His background and expertise will be a valuable addition to the board.”

< back to list